Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 11/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725720 | 0.87 | CNR1 (0.47) | CNR1NAMPTHTR1ASIGMAR1MEN1 | |
| SCHEMBL1726251 | 0.87 | MAPT (0.46) | CNR1NAMPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL1578403 | 0.84 | ALDH1A1 (0.43) | NAMPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1725351 | 0.83 | TRPV1 (0.42) | CNR1NAMPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL1578464 | 0.82 | MMP2 (0.40) | NAMPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL27948508 | 0.79 | CNR1 (0.47) | CNR1NAMPTALDH1A1SMN1; SMN2HTR1A | |
| SCHEMBL1578462 | 0.78 | MEN1 (0.43) | NAMPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1725911 | 0.77 | NAMPT (0.41) | NAMPTSMN1; SMN2 | |
| SCHEMBL1578543 | 0.77 | TRPV1 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4813430 | 0.75 | NAMPT (0.49) | CNR1NAMPTSMN1; SMN2SIGMAR1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289518-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI (FR) | 2012-11-15 | — | — | US | claimed |
| US-8247404-B2 | Derivatives of 2-oxoalkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same | SANOFI (FR) | 2012-08-21 | — | — | US | claimed |
| WO-2011144835-A3 | TUBULAR PHOTOVOLTAIC DEVICE FOR PRODUCING ELECTRICAL ENERGY | THEROND PATRICK (FR) | 2012-05-10 | — | — | WO | claimed |
| EP-2310383-B1 | DERIVATIVES OF 2-OXO-ALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI SA (FR) | 2011-11-30 | — | — | EP | claimed |
| US-20110144122-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | claimed |
| US-20170189522-A1 | PHARMACEUTICAL COMBINATIONS FOR IMMUNOTHERAPY | TECHNISCHE UNIVERSITAT DRESDEN (DE) | 2017-07-06 | — | — | US | disclosed |
| WO-2015181298-A1 | PHARMACEUTICAL COMBINATIONS FOR IMMUNOTHERAPY | Technische Universität Dresden (DE) | 2015-12-03 | — | — | WO | disclosed |
| US-20120289518-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI (FR) | 2012-11-15 | — | — | US | disclosed |
| US-8247404-B2 | Derivatives of 2-oxoalkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same | SANOFI (FR) | 2012-08-21 | — | — | US | disclosed |
| WO-2011144835-A3 | TUBULAR PHOTOVOLTAIC DEVICE FOR PRODUCING ELECTRICAL ENERGY | THEROND PATRICK (FR) | 2012-05-10 | — | — | WO | disclosed |
| EP-2310383-B1 | DERIVATIVES OF 2-OXO-ALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI SA (FR) | 2011-11-30 | — | — | EP | disclosed |
| US-20110144122-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144122-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | PKD2, OPRM1, DHFR | CNR1 47/4885NAMPT 1922/4885ALDH1A1 37/4885 |
| US-20120289518-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | PKD2, OPRM1, DHFR | CNR1 47/4885NAMPT 1922/4885ALDH1A1 37/4885 |
| US-20170189522-A1 | PHARMACEUTICAL COMBINATIONS FOR IMMUNOTHERAPY | TLR9, TLR7, TLR3 | CNR1 176/4885NAMPT 826/4885ALDH1A1 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.